Nurse Julia Fontenot, 27, Shows No Evidence of Stage 4 Sarcoma After 3 Years

Q: When a deadly brain recurrence turned out to be dead tissue, what cutting-edge scans saved this stage 4 cancer survivor?

The scans that likely made the difference were advanced brain imaging used to tell radiation necrosis from true tumor regrowth — especially perfusion MRI, MR spectroscopy and PET/CT. In Fontenot’s case, the “deadly recurrence” seen after prior brain radiation ultimately proved to be necrotic tissue, a known complication called radiation necrosis. Standard MRI often cannot reliably distinguish that from an active metastasis because both can appear as new enhancing masses with swelling. That is where newer imaging comes in. Perfusion MRI looks at blood flow inside the lesion; recurrent tumor usually shows higher vascularity, while necrotic tissue tends to have lower perfusion. MR spectroscopy adds metabolic clues by measuring tissue chemicals, helping doctors judge whether a mass is biologically active cancer or treatment damage. PET/CT can provide another layer of evidence, especially with tracers used in neuro-oncology to detect metabolically active tumor versus inactive tissue injury. The web evidence specifically points to MRI perfusion, MR spectroscopy and PET/CT as the leading tools for this problem, with amino-acid PET tracers such as 11C-methionine or 18F-FET considered particularly useful where available. Even so, the literature also shows these cases remain difficult, and surgery is sometimes still needed for a definitive answer — exactly what happened in Fontenot’s September 2024 operation, when pathology showed dead tissue, not returning brain cancer.

1 articles · Updated · TODAY · Aug 14

Three years after an August 2023 diagnosis, Julia Fontenot, 27, has no visible cancer on her latest PET scan despite still carrying a Stage 4 synovial sarcoma diagnosis.
A persistent cough led doctors to a large lung mass, and within days scans found three brain tumors — one bleeding — plus spread elsewhere, prompting emergency brain surgery, radiation and eight months of chemotherapy.
Her treatment continued through 2024 and 2025 with a right lung resection, radiation for a rib lesion and lung spot, and surgeries to remove small tumors on her thigh and shoulder as they appeared.
Median survival for metastatic synovial sarcoma is about 18 months and less than six months when it reaches the brain, her doctor said, making her current full-time nursing work and normal life with her husband a rare outcome.

Sources

TODAY9d ago

Nurse Julia Fontenot, 27, Thrives After Aggressive Synovial Sarcoma Treatment

When a deadly brain recurrence turned out to be dead tissue, what cutting-edge scans saved this stage 4 cancer survivor?

Could a newly approved breakthrough T-cell immunotherapy be the secret behind this 27-year-old's miraculous survival against aggressive stage 4 sarcoma?

How did a young nurse overcome a terminal brain tumor diagnosis to return to the frontlines of healthcare completely cancer-free?

Sources

1 total

TODAY9d ago

Nurse Julia Fontenot, 27, Thrives After Aggressive Synovial Sarcoma Treatment

Nurse Julia Fontenot, 27, Shows No Evidence of Stage 4 Sarcoma After 3 Years

Summary

Sources

Insights

Related Stories

Sources

Related Stories